Stock listing
Dusseldorf:OL0 Devyser Diagnostics AB Aktie
German listing (Dusseldorf) of Devyser Diagnostics AB · home listing Stockholm:DVYSR
Follow Devyser Diagnostics AB into a list and get an email when it puts out news.
Home listing price · OMXSTO:DVYSR
60.00 SEK -2.80 (-4.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:DVYSR
- Day range
- 59.00 – 62.50 SEKNov 20, 2026
- Volume
- 24,844 sharesNov 20, 2026
- Market cap
- 1.01B SEKAt the close on Nov 20, 2026 · price × 16.89M shares outstanding
- 52-week range
- 48.50 – 120.00 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 1.09M SEKMedian day 13,654 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:DVYSR · Home | 60.00 SEK | -2.80 (-4.5%) | 24,844 | 62.30 | 62.50 | 59.00 | 62.80 | Close on Nov 20, 2026 |
| Frankfurt:OL0 | €5.24 EUR | -0.36 (-6.4%) | — | €5.55 | €5.55 | €5.24 | €5.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:DVYSR · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 60.00 | -2.80 | -4.5% | 62.30 | 62.50 | 59.00 | 24,844 | |
| 62.80 | -0.30 | -0.5% | 63.00 | 64.70 | 61.50 | 8,861 | |
| 63.10 | -1.40 | -2.2% | 63.30 | 64.50 | 63.10 | 10,754 | |
| 64.50 | -1.10 | -1.7% | 66.40 | 66.40 | 64.10 | 13,115 | |
| 65.60 | +0.60 | +0.9% | 65.10 | 67.70 | 65.10 | 4,823 | |
| 65.00 | -1.70 | -2.5% | 66.80 | 67.90 | 65.00 | 5,625 | |
| 66.70 | +1.90 | +2.9% | 65.00 | 68.60 | 64.00 | 33,377 | |
| 64.80 | -2.80 | -4.1% | 68.40 | 68.40 | 63.90 | 24,044 | |
| 67.60 | +3.30 | +5.1% | 65.30 | 68.70 | 64.40 | 37,401 | |
| 64.30 | -0.50 | -0.8% | 65.20 | 65.90 | 63.00 | 21,997 | |
| 64.80 | +3.30 | +5.4% | 65.10 | 68.00 | 62.00 | 72,273 | |
| 61.50 | +6.50 | +11.8% | 55.90 | 63.00 | 55.90 | 57,172 | |
| 55.00 | -3.00 | -5.2% | 58.00 | 58.00 | 55.00 | 10,643 | |
| 58.00 | -1.50 | -2.5% | 59.40 | 59.40 | 58.00 | 61,174 | |
| 59.50 | +4.50 | +8.2% | 56.50 | 59.80 | 56.40 | 24,045 | |
| 55.00 | +4.60 | +9.1% | 51.10 | 55.00 | 49.80 | 52,265 | |
| 50.40 | -0.60 | -1.2% | 50.10 | 51.40 | 50.00 | 14,472 | |
| 51.00 | +1.00 | +2.0% | 50.10 | 51.30 | 50.10 | 10,359 | |
| 50.00 | -0.50 | -1.0% | 50.10 | 50.80 | 49.60 | 8,742 | |
| 50.50 | 0.00 | 0.0% | 50.60 | 53.10 | 49.90 | 28,473 | |
| 50.50 | -0.50 | -1.0% | 50.60 | 51.10 | 49.70 | 8,556 | |
| 51.00 | +1.00 | +2.0% | 50.00 | 51.10 | 49.50 | 10,048 | |
| 50.00 | -0.40 | -0.8% | 50.80 | 51.60 | 49.85 | 8,091 | |
| 50.40 | -0.10 | -0.2% | 50.50 | 50.50 | 48.50 | 19,679 | |
| 50.50 | -0.30 | -0.6% | 51.30 | 52.00 | 50.00 | 15,952 | |
| 50.80 | +1.05 | +2.1% | 50.50 | 51.30 | 50.00 | 21,150 | |
| 49.75 | -1.05 | -2.1% | 50.50 | 50.80 | 49.75 | 15,458 | |
| 50.80 | -0.30 | -0.6% | 51.80 | 52.10 | 50.20 | 18,324 | |
| 51.10 | -1.50 | -2.9% | 52.10 | 52.10 | 51.10 | 16,472 | |
| 52.60 | -0.90 | -1.7% | 53.10 | 53.50 | 52.10 | 9,387 | |
| 53.50 | -0.50 | -0.9% | 54.60 | 55.50 | 52.40 | 64,621 | |
| 54.00 | -0.80 | -1.5% | 55.00 | 56.40 | 52.30 | 33,955 | |
| 54.80 | +3.70 | +7.2% | 51.20 | 55.60 | 51.00 | 23,522 | |
| 51.10 | +0.30 | +0.6% | 50.80 | 51.50 | 50.60 | 45,213 | |
| 50.80 | +0.30 | +0.6% | 50.80 | 50.90 | 50.20 | 28,554 | |
| 50.50 | -0.60 | -1.2% | 51.10 | 51.20 | 50.10 | 50,666 | |
| 51.10 | -0.60 | -1.2% | 51.70 | 51.70 | 50.70 | 8,979 | |
| 51.70 | -0.60 | -1.1% | 53.70 | 53.70 | 51.20 | 6,009 | |
| 52.30 | -0.70 | -1.3% | 53.00 | 53.00 | 51.70 | 3,355 | |
| 53.00 | +0.20 | +0.4% | 53.00 | 53.50 | 52.20 | 10,360 | |
| 52.80 | -0.10 | -0.2% | 52.90 | 53.30 | 52.20 | 6,190 | |
| 52.90 | -0.60 | -1.1% | 53.50 | 54.00 | 52.30 | 16,915 | |
| 53.50 | -1.30 | -2.4% | 54.80 | 56.80 | 52.90 | 13,772 | |
| 54.80 | -0.20 | -0.4% | 55.00 | 55.00 | 52.90 | 13,069 | |
| 55.00 | +1.00 | +1.9% | 53.70 | 55.00 | 53.60 | 4,445 | |
| 54.00 | -0.90 | -1.6% | 54.70 | 54.70 | 53.00 | 27,913 | |
| 54.90 | -0.80 | -1.4% | 56.50 | 56.50 | 54.50 | 8,966 | |
| 55.70 | -1.10 | -1.9% | 56.80 | 56.80 | 55.20 | 9,424 | |
| 56.80 | -2.00 | -3.4% | 59.90 | 59.90 | 56.20 | 15,432 | |
| 58.80 | -1.20 | -2.0% | 59.10 | 59.70 | 58.80 | 3,752 | |
| 60.00 | +0.40 | +0.7% | 60.40 | 60.40 | 58.70 | 4,696 | |
| 59.60 | -0.30 | -0.5% | 61.10 | 61.10 | 59.00 | 3,066 | |
| 59.90 | +0.30 | +0.5% | 60.40 | 60.40 | 59.00 | 10,905 | |
| 59.60 | -0.10 | -0.2% | 59.90 | 60.20 | 59.30 | 6,118 | |
| 59.70 | +1.20 | +2.1% | 58.90 | 59.90 | 58.00 | 25,748 | |
| 58.50 | -0.10 | -0.2% | 59.40 | 59.40 | 58.10 | 8,015 | |
| 58.60 | -0.30 | -0.5% | 59.00 | 59.60 | 58.30 | 15,352 | |
| 58.90 | -1.10 | -1.8% | 59.30 | 60.40 | 58.80 | 8,483 | |
| 60.00 | +0.30 | +0.5% | 59.60 | 60.70 | 59.20 | 20,243 | |
| 59.70 | 0.00 | 0.0% | 60.00 | 60.00 | 58.90 | 10,851 | |
| 59.70 | +0.10 | +0.2% | 59.20 | 60.00 | 59.00 | 10,829 | |
| 59.60 | -0.20 | -0.3% | 59.50 | 62.10 | 58.70 | 13,535 | |
| 59.80 | -1.30 | -2.1% | 61.20 | 62.20 | 59.60 | 22,560 | |
| 61.10 | +0.90 | +1.5% | 65.70 | 65.70 | 60.30 | 6,980 |
- Ticker
- Dusseldorf:OL0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Apr 27, 2026
Devyser Diagnostics AB publishes quarterly report for the period January to March 2026
Latest earnings call · Jul 20, 2026
Devyser Diagnostics (Stockholm:DVYSR) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 3, 2026
Q3 2026 Earnings Presentation
Earnings · 22 slides
Latest news
Devyser Diagnostics AB publishes quarterly report for the period January to March 2026
Apr 27, 2026
Closed 95.90 (+7.2%) on Apr 27, 2026
Devyser announces that Chief Commercial Officer will leave the company
Apr 7, 2026
Closed 76.80 (+3.2%) on Apr 8, 2026
Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares
Apr 1, 2026
Closed 78.60 (+3.8%) on Apr 1, 2026
Devyser Diagnostics AB publishes year-end report for January to December 2025
Feb 12, 2026
Closed 105.40 (+3.5%) on Feb 12, 2026
Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market
Feb 11, 2026
Closed 105.40 (+3.5%) on Feb 12, 2026
Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test
Nov 28, 2025
Closed 113.40 (+6.0%) on Nov 28, 2025
Devyser Diagnostics AB on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 6 in the last 12 months · 10 in all · newest Apr 27, 2026 · oldest 2025
- Calls
- 10 calls with a replay · 10 with a transcript · latest Jul 20, 2026
- Decks
- 13 decks · latest Nov 3, 2026
Where Devyser Diagnostics AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:DVYSR · Home listing | Stockholm | Sweden | SEK |
| LS Exchange:A3C811 | LS Exchange | Germany | EUR |
| gettex:OL0 | gettex | Germany | EUR |
| Lang & Schwarz:A3C811 | Lang & Schwarz | Germany | EUR |
| Munich:OL0 | Munich | Germany | EUR |
| Frankfurt:OL0 | Frankfurt | Germany | EUR |
| Stuttgart:OL0 | Stuttgart | Germany | EUR |
| Dusseldorf:OL0 · This page | Dusseldorf | Germany | EUR |
| OTC:DVYSF | OTC | United States | USD |
Valuation
P/E 39.9× against a median of 25.0×: 4th lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 968.7M SEK
- P/E
- 39.9×
- EV/sales
- 3.8×
- EV/EBITDA
- 17.5×
- Price/book
- 2.6×
- Gross margin
- 80.1%
- Operating margin
- 11.0%
- Net margin
- 10.0%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Devyser Diagnostics AB · OMXSTO:DVYSR | US$99.24M | US$94.86M | 39.9× | 3.8× | 17.5× | 2.6× | 10.0% | 0.1× | n/a |
| Burning Rock Biotech Ltd. · NASDAQ:BNR | US$116.7M | US$60.54M | n/a | 0.8× | n/a | 1.6× | −13.6% | 0.1× | 1.51 |
| BIODYNE Co., Ltd. · KRX:314930 | US$115.0M | US$104.0M | 182× | 19.9× | 70.7× | 3.5× | 12.1% | 0.0× | n/a |
| Photocure ASA · OSL:PHO | US$113.9M | US$97.23M | 22.9× | 1.4× | 6.1× | 1.9× | 7.1% | 0.0× | n/a |
| ArcticZymes Technologies ASA · OSL:AZT | US$108.4M | US$80.84M | 66.1× | 6.2× | 24.6× | 3.0× | 12.7% | 0.0× | n/a |
| NanoenTek, Inc. · KRX:039860 | US$107.8M | US$71.26M | 24.8× | 2.2× | 17.4× | 1.5× | 13.3% | 0.0× | n/a |
| BICO Group AB Class B · OMXSTO:BICO | US$102.7M | US$90.50M | n/a | 0.6× | 2.1× | 0.8× | −28.3% | 0.3× | n/a |
| Quanterix Corporation · NASDAQ:QTRX | US$93.06M | US$47.06M | n/a | 0.3× | n/a | 0.4× | −75.0% | 0.1× | 1.87 |
| Exagen Inc. · NASDAQ:XGN | US$92.10M | US$86.82M | n/a | 1.2× | n/a | 6.7× | −25.1% | 1.7× | 2.52 |
| Biodesix, Inc. · NASDAQ:BDSX | US$83.83M | US$105.4M | n/a | 1.0× | n/a | 9.7× | −25.7% | 5.8× | 1.56 |
| Bonraybio Co. Ltd. · TWSE:6955 | US$81.85M | US$65.60M | 25.0× | 6.5× | 18.1× | 4.1× | 32.5% | 0.0× | n/a |
| Median of the others | US$105.3M | US$83.83M | 25.0× | 1.3× | 17.8× | 2.5× | −3.3% | 0.1× | 1.72 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 100.17 SEK · Analysts' mean
- EPS, year to Dec 2026
- 0.73 · 2 analysts
- Revenue, year to Dec 2026
- 247.1M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jan Wahlström | CEO |
| Niklas Axelsson | CFO |
| Sabina Berlin | VP IR & Corporate Affairs |
| Olle Myrberg | VP Quality & Regulatory Affairs |
| Robin Sortebech | VP Supply Chain |
| Michael Uhlin | CSO |
Board
| Director | Role |
|---|---|
| Mia Arnhult | Chairman |
| Fredrik Dahl | Board member |
| Olof Ericsson | Board member |
| Pia Gideon | Board member |
| Thomas Eklund | Board member |
Events
- Next results
- Feb 16, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Devyser Diagnostics (Stockholm:DVYSR) Q2 2026 Earnings Call | Mon, Jul 20, 2026 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q1 2026 Earnings Call | Mon, Apr 27, 2026 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q4 2025 Earnings Call | Thu, Feb 12, 2026 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q2 2025 Earnings Call | Tue, Jul 22, 2025 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q1 2025 Earnings Call | Tue, Apr 29, 2025 · 5:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 7:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q3 2024 Earnings Call | Wed, Oct 30, 2024 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q2 2024 Earnings Call | Tue, Jul 23, 2024 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q1 2024 Earnings Call | Wed, May 08, 2024 · 3:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · Before open | +5.4% |
| Q2 2026 | Jul 19, 2026 · After close | 0.0% |
| Q1 2026 | Apr 27, 2026 · Before open | +7.2% |
| Q4 2025 | Feb 11, 2026 · After close | +3.5% |
| Q3 2025 | Nov 4, 2025 · After close | −9.8% |
| Q2 2025 | Jul 22, 2025 · Before open | +9.8% |
| Q1 2025 | Apr 29, 2025 · Before open | −0.5% |
| Q4 2024 | Feb 13, 2025 · Before open | −7.2% |
| Q3 2024 | Oct 30, 2024 · Before open | −1.5% |
| Q2 2024 | Jul 23, 2024 · Before open | −0.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | +5.8% |
| Q4 2023 | Feb 19, 2024 · After close | +7.2% |
| Q3 2023 | Nov 9, 2023 · Before open | +3.1% |
| Q2 2023 | Aug 23, 2023 · Before open | −1.0% |
| Q1 2023 | May 9, 2023 · Before open | −2.8% |
| Q4 2022 | Feb 21, 2023 · Before open | +1.5% |
| Q3 2022 | Nov 10, 2022 · Before open | −1.5% |
| Q2 2022 | Aug 24, 2022 · Before open | −0.2% |
| Q1 2022 | May 11, 2022 · Before open | −0.7% |
| Q4 2021 | Feb 24, 2022 · Before open | −2.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 22 slides | Nov 3, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 23 slides | Jul 20, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 23 slides | Apr 27, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 24 slides | Nov 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 23 slides | Jul 22, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 24 slides | Apr 29, 2025 |
| Investor Day (November 2024) | Investor day | 76 slides | Nov 25, 2024 |
| Q3 2024 Earnings Presentation | Earnings | 21 slides | Oct 30, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 21 slides | Jul 23, 2024 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2024 Earnings Presentation | Earnings | 26 slides | May 8, 2024 |
| Devyser — Q2 2023 Earnings Presentation | Earnings | 21 slides | Aug 23, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 18 slides | May 9, 2023 |
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 250.5M | 216.9M | 169.3M | 126.6M | 93.5M | 65.7M | 64.3M | 48.1M |
| Cost of revenue | 48.6M | 44.2M | 21.2M | 20.8M | 18.8M | 9.04M | 12.0M | 13.3M |
| Gross profit | 201.9M | 172.7M | 148.1M | 105.8M | 74.7M | 56.6M | 52.3M | 34.8M |
| Research and development | 18.0M | 43.1M | 41.1M | 28.6M | 20.8M | 21.7M | 9.90M | 8.62M |
| Selling, general and administrative | 56.0M | 51.3M | 42.0M | 37.9M | 28.8M | 11.7M | ||
| Operating income | 10.6M | -58.3M | -56.5M | -54.9M | -21.8M | -6.96M | 8.65M | -3.51M |
| Depreciation and amortization | 27.1M | 27.7M | 9.80M | 6.16M | 3.28M | 2.96M | 2.32M | 1.25M |
| EBITDA | 37.7M | -30.6M | -46.7M | -48.8M | -18.5M | -3.99M | 11.0M | -2.27M |
| Interest expense | 13.6M | 3.50M | 800.0K | 500.0K | 939.0K | 925.0K | 785.0K | 596.0K |
| Income before tax | -2.60M | -57.6M | -54.4M | -52.7M | -22.3M | -10.9M | 10.2M | -232.0K |
| Income tax | 5.80M | 3.90M | -800.0K | -6.80M | -1.18M | -985.0K | 2.62M | -751.0K |
| Net income | -8.40M | -61.5M | -53.6M | -46.0M | -20.7M | -10.9M | 7.01M | 519.0K |
| Earnings per share, basic | -0.51 | -3.75 | -3.31 | -2.89 | -1.85 | -3.76 | 2.31 | 0.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 77.5M | 144.5M | 262.9M | 363.6M | 377.6M | 8.34M | 10.4M | 7.54M |
| Short-term investments | -1 | |||||||
| Receivables | 67.0M | 74.6M | 45.3M | 33.4M | 26.2M | 25.1M | 17.2M | 15.3M |
| Inventory | 37.0M | 30.2M | 20.6M | 10.3M | 6.95M | 5.45M | 3.87M | 4.13M |
| Current assets | 204.3M | 252.3M | 341.8M | 412.1M | 412.7M | 39.7M | 32.4M | 27.8M |
| Goodwill | 6.60M | 7.00M | 6.70M | 6.77M | 236.0K | 236.0K | ||
| Total assets | 469.7M | 473.8M | 510.1M | 500.6M | 456.9M | 74.4M | 73.7M | 48.2M |
| Accounts payable | 17.9M | 12.6M | 14.2M | 9.60M | 9.66M | 6.34M | 3.40M | 3.17M |
| Current liabilities | 70.9M | 72.6M | 62.9M | 51.2M | 29.4M | 28.0M | 15.9M | 9.75M |
| Long-term debt | 300.0K | 300.0K | 600.0K | 600.0K | 0 | 4.22M | ||
| Total debt | 51.9M | 59.1M | 74.8M | 21.2M | 13.0M | 21.5M | 23.9M | 9.72M |
| Total liabilities | 115.4M | 124.8M | 125.0M | 69.2M | 40.2M | 43.6M | 36.7M | 18.3M |
| Shareholders' equity | 354.3M | 349.1M | 385.1M | 431.4M | 416.7M | 30.8M | 37.0M | 30.0M |
| Shares outstanding | 16.6M | 16.4M | 16.2M | 15.9M | 11.2M | 2.90M | 3.03M | 3.00M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 8.20M | -46.8M | -69.7M | -40.5M | -16.5M | 627.0K | 14.6M | 6.02M |
| Capital spending | -1.50M | -76.9M | -32.0M | -25.8M | -8.80M | -3.41M | -9.31M | -5.06M |
| Free cash flow | 6.70M | -123.7M | -101.7M | -66.3M | -25.3M | -2.79M | 5.32M | 957.0K |
| Cash from investing | -70.7M | -76.9M | -32.0M | -23.9M | -10.3M | -4.71M | -9.96M | -5.06M |
| Cash from financing | -2.80M | 7.80M | -200.0K | 48.9M | 395.9M | 2.27M | -1.87M | -974.0K |
| Change in cash | -67.0M | -118.4M | -100.7M | -14.0M | 369.3M | -2.04M | 2.84M | -17.0K |
Cap table
Built by 6ix from Devyser Diagnostics AB’s releases
- Common shares
- 16,889,806
- Fully diluted
- 16,889,806
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 16,889,806 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 16,889,806 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Fredrik Dahl | Board member · Since at least Jul 22, 2025 |
| Jan Wahlström | CEO · Since at least Apr 27, 2026 |
| Mia Arnhult | Chairman · Since at least Jul 22, 2025 |
| Michael Uhlin | CSO · Since at least Apr 29, 2025 |
| Niklas Axelsson | CFO · Since at least Nov 4, 2026 |
| Olle Myrberg | VP Quality & Regulatory Affairs · Since at least Apr 29, 2025 |
| Olof Ericsson | Board member · Since at least Jul 22, 2025 |
| Pia Gideon | Board member · Since at least Jul 22, 2025 |
| Robin Sortebech | VP Supply Chain · Since at least Apr 29, 2025 |
| Sabina Berlin | VP IR & Corporate Affairs · Since at least Apr 27, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Thomas Eklund | Board member · Since at least Jul 22, 2025 |
Log in to ask 6ix AI your own questions about Devyser Diagnostics AB.